baricitinib · Olumiant

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Rheumatoid Arthritis, Alopecia Areata, COVID-19

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Atopic Dermatitis · Phase 3 · investigational in the US

Also approved (6)
CA
  • OLUMIANT (baricitinib tablets) is indicated for: Rheumatoid Arthritis (RA) • In combination with methotrexate (MTX), for reducing the signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). OLUMIANT may be used as monotherapy in cases of intolerance to MTX. Limitations of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended (see 7 WARNINGS AND...
Product first approved 2018Health Canada
JP
  • Rheumatoid arthritis with inadequate response to standard of care (2 mg and 4 mg tablets)
Product first approved 2017pharmaceuticalprocessingworld.com
EU
  • Olumiant: moderate to severe active rheumatoid arthritis in adults; holder Eli Lilly Nederland B.V.EMA
  • Moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy (Olumiant)EMA
  • Treatment of active juvenile idiopathic arthritis in patients 2 years of age and older (Olumiant)Outside this platform's coverageEMA
  • Treatment of severe alopecia areata in adult and adolescent patients 12 years of age and older (Olumiant)EMA
Product first approved 2017

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (46)
Alopecia Areata
NCT05723198 · Eli Lilly and Company
2023-02-27 – 2033-09 · Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
What this study did
Atopic Dermatitis
NCT03952559 · Eli Lilly and Company
2019-05-24 – 2026-05-22 · Atopic Dermatitis
What this study did
NCT03334435 · Eli Lilly and Company
2018-03-28 – 2023-07-12 · Atopic Dermatitis
What this study did
NCT03559270 · Eli Lilly and Company
2018-06-27 – 2022-06-13 · Atopic Dermatitis
What this study did
NCT03435081 · Eli Lilly and Company
2018-02-20 – 2021-08-16 · Atopic Dermatitis
What this study did
NCT03733301 · Eli Lilly and Company
2018-11-16 – 2019-08-22 · Atopic Dermatitis
What this study did
COVID-19
NCT04381936 · University of Oxford
2020-03-19 – 2038-09-30 · Pneumonia
What this study did
NCT05858515 · Vanderbilt University Medical Center
2024-10-21 – 2029-12-30 · Post-Acute COVID-19 Syndrome
What this study did
NCT02735707 · UMC Utrecht
2016-04-11 – 2029-02 · Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
What this study did
NCT06631287 · Wes Ely
2024-10-21 – 2027-07-01 · Long COVID, Sars-CoV-2 Infection, Coronavirus Infections, COVID-19
What this study did
NCT05056558 · Incepta Pharmaceuticals Ltd
2020-07-30 – 2026-04-12 · Covid19
What this study did
NCT05074420 · Eli Lilly and Company
2021-12-21 – 2024-11-04 · Covid19, Corona Virus Infection
What this study did
NCT04890626 · Instituto de Investigación Hospital Universitario La Paz
2020-04-04 – 2023-07-17 · SARS-CoV-2 Infection
What this study did
NCT04832880 · ASST Fatebenefratelli Sacco
2021-04-06 – 2022-12 · Covid19
What this study did
NCT04970719 · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
2021-07-10 – 2021-12 · COVID-19 Pneumonia
What this study did
NCT04640168 · National Institute of Allergy and Infectious Diseases (NIAID)
2020-12-02 – 2021-06-18 · COVID-19
What this study did
NCT04693026 · M Abdur Rahim Medical College and Hospital
2020-09-10 – 2021-03-05 · Covid19, Covid-19 ARDS
What this study did
Rheumatoid Arthritis
NCT03414502 · University of Nebraska
2007-12-10 – 2029-03 · Rheumatoid Arthritis
What this study did
NCT04870203 · University Hospital, Bordeaux
2021-07-15 – 2027-03 · Rheumatoid Arthritis
What this study did
NCT03701789 · University of Erlangen-Nürnberg Medical School
2018-09-11 – 2021-10-11 · Rheumatoid Arthritis, Bone Density, Finger Joints
What this study did
NCT01885078 · Eli Lilly and Company
2013-06-27 – 2020-11-12 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07543458 · Oxford University Clinical Research Unit, Vietnam
2026-10-01 – 2031-07-31 · Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections, Hemorrhagic Fever
What this study did
NCT07222137 · Eli Lilly and Company
2026-01-12 – 2031-07 · Diabetes Mellitus, Type 1
What this study did
NCT03773965 · Eli Lilly and Company
2019-04-05 – 2031-07 · Juvenile Idiopathic Arthritis
What this study did
NCT05651880 · University Hospital, Rouen
2026-07 – 2029-12 · Active Non-anterior Non-infectious Uveitis
What this study did
NCT07279688 · University Hospital, Brest
2025-12-18 – 2029-06 · Polymyalgia Rheumatica (PMR)
What this study did
NCT07222332 · Eli Lilly and Company
2026-02-05 – 2028-07 · Diabetes Mellitus, Type 1
What this study did
NCT04972760 · Assistance Publique - Hôpitaux de Paris
2022-08-31 – 2028-02-28 · Dermatomyositis
What this study did
NCT04088396 · Eli Lilly and Company
2020-02-12 – 2026-10 · Systemic Juvenile Idiopathic Arthritis
What this study did
NCT06936215 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2024-01-01 – 2025-05 · Diffuse Cutaneous Systemic Sclerosis
What this study did
NCT03843125 · Eli Lilly and Company
2019-09-09 – 2022-04-01 · Systemic Lupus Erythematosus
What this study did
NCT03616912 · Eli Lilly and Company
2018-08-02 – 2022-03-09 · Systemic Lupus Erythematosus
What this study did
NCT03773978 · Eli Lilly and Company
2018-12-17 – 2022-01-26 · Juvenile Idiopathic Arthritis
What this study did
Phase 2/3 (11)
Alopecia Areata
COVID-19
NCT04891133 · Oslo University Hospital
2021-06-03 – 2023-01-23 · COVID-19, Emerging Infectious Disease
What this study did
NCT04340232 · University of Colorado, Denver
2021-03 – 2021-10 · COVID-19
What this study did
NCT04320277 · Hospital of Prato
2020-05-16 – 2020-07-30 · Pharmacological Action
What this study did
NCT04358614 · Fabrizio Cantini
2020-03-16 – 2020-04-07 · COVID, Pneumonia
What this study did
Other / comorbidity
NCT07449910 · The First Affiliated Hospital of University of Science and Technology of China
2026-03-17 – 2028-01-31 · Acute Ichemic Stroke, Anterior Cerebral Artery Stroke, Baricitinib
What this study did
NCT06475820 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2023-12-01 – 2027-04-01 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes
What this study did
NCT05914584 · Nantes University Hospital
2023-07-01 – 2025-12-31 · Hospital-acquired Pneumonia
What this study did
NCT06768840 · South Valley University
2024-10-02 – 2025-10 · Vitiligo, Generalized
What this study did
NCT04517253 · Eli Lilly and Company
2020-10-27 – 2024-11-28 · Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy, Aicardi Goutieres Syndrome
What this study did
NCT05686746 · Assiut University
2022-06-01 – 2023-08-01 · Lupus or SLE, Nephritis
What this study did
Phase 2 (55)
Alopecia Areata
NCT06797310 · National Taiwan University Hospital
2025-01-23 – 2026-12-31 · Alopecia Areata
What this study did
Atopic Dermatitis
NCT02576938 · Eli Lilly and Company
2016-02 – 2017-03 · Atopic Dermatitis
What this study did
COVID-19
NCT04321993 · Lisa Barrett
2020-04-17 – 2024-04 · COVID-19
What this study did
NCT04346147 · Hospital Universitario de Fuenlabrada
2020-05-07 – 2021-09 · COVID-19 Pneumonia
What this study did
NCT04373044 · University of Southern California
2020-05-01 – 2021-05-12 · Symptomatic COVID-19 Infection Laboratory-Confirmed
What this study did
NCT04399798 · Fondazione IRCCS Policlinico San Matteo di Pavia
2020-05-15 – 2020-11-15 · Corona Virus Infection
What this study did
NCT04393051 · Azienda Ospedaliero, Universitaria Pisana
2020-05-20 – 2020-07-30 · Covid-19, SARS-CoV 2, SARS Pneumonia
What this study did
Rheumatoid Arthritis
NCT03755466 · Shinshu University
2018-11-21 – 2025-11-20 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07081763 · ANRS, Emerging Infectious Diseases
2027-05 – 2033-05 · HIV-1-infection
What this study did
NCT06381661 · Assistance Publique - Hôpitaux de Paris
2026-07-09 – 2031-07-09 · Sepsis
What this study did
NCT06923072 · National Heart, Lung, and Blood Institute (NHLBI)
2026-02-18 – 2030-12-15 · Kohlmeier-Degos Disease, Malignant Atrophic Papulosis, Degos Disease, Papulosis, Malignant Atrophic
What this study did
NCT07779642 · University of Colorado, Denver
2026-09 – 2030-09 · ARDS (Acute Respiratory Distress Syndrome), Acute Hypoxic Respiratory Failure
What this study did
NCT07268534 · Assistance Publique - Hôpitaux de Paris
2026-04-01 – 2030-04-01 · Folliculitis Decalvans (FD)
What this study did
NCT07003997 · Emory University
2025-09-03 – 2030-02 · Major Depressive Disorder
What this study did
NCT06868381 · Stanford University
2026-04-01 – 2028-12-01 · Cardiac Sarcoidosis
What this study did
NCT06490757 · Assistance Publique - Hôpitaux de Paris
2024-10-02 – 2028-09-02 · Inflammatory Hepatocellular Adenoma
What this study did
NCT07669675 · Peking University People's Hospital
2026-07-01 – 2028-08-31 · ITP - Immune Thrombocytopenia
What this study did
NCT06849908 · Peking Union Medical College Hospital
2024-11-08 – 2028-06-30 · Behcet Syndrome, Intestinal Type
What this study did
NCT05452564 · William Tyor
2023-05-18 – 2028-01 · Human Immunodeficiency Virus
What this study did
NCT07209267 · Emory University
2026-12 – 2028-01 · HIV Infection, HIV
What this study did
NCT05849038 · Emory University
2023-12-11 – 2027-11 · HIV, Depression, Anhedonia
What this study did
NCT07608796 · Emory University
2026-10 – 2027-10 · Depressive Symptoms, Cognitive Symptom
What this study did
NCT06439615 · Tang-Du Hospital
2024-08-01 – 2027-06-30 · Spontaneous Subarachnoid Hemorrhage
What this study did
NCT06768294 · I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
2025-01 – 2027-01 · Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis
What this study did
NCT06065046 · Tang-Du Hospital
2023-11-24 – 2026-12-31 · Traumatic Brain Injury
What this study did
NCT06158113 · University of North Carolina, Chapel Hill
2024-03-13 – 2026-09-09 · Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus
What this study did
NCT07028385 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
2025-09-22 – 2026-06-30 · HIV
What this study did
NCT07843732 · Raven Clinical Research
2024-10-22 – 2026-04-28 · Central Centrifugal Cicatricial Alopecia
What this study did
NCT05237388 · Duke University
2023-04-20 – 2026-04-03 · Chronic Kidney Diseases
What this study did
NCT05524311 · Assistance Publique - Hôpitaux de Paris
2022-11-10 – 2026-01-02 · Juvenile Dermatomyositis
What this study did
NCT05852171 · First Affiliated Hospital of Zhejiang University
2023-05-04 – 2025-12-31 · Mastitis Chronic, Idiopathic Granulomatous Mastitis
What this study did
NCT06737705 · De-zhi Kang
2025-01-01 – 2025-08-18 · Intracerebral Hemorrhage
What this study did
NCT05932524 · Peking University People's Hospital
2023-07-07 – 2025-06 · Immune Thrombocytopenia
What this study did
NCT04901325 · Oregon Health and Science University
2023-10-03 – 2025-05-07 · Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
What this study did
NCT05852847 · Peking University People's Hospital
2023-05-16 – 2025-05 · Immune Thrombocytopenia
What this study did
NCT06114407 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2023-10-30 – 2024-12-30 · Spondyloarthritis, Axial
What this study did
NCT05016297 · Peking Union Medical College Hospital
2022-07-14 – 2024-11-22 · Sjogren's Syndrome
What this study did
NCT06662721 · Liu Tian
2023-04-03 – 2024-06-08 · Takayasu Arteritis
What this study did
NCT04774224 · St Vincent's Institute of Medical Research
2020-10-30 – 2024-05-06 · Type 1 Diabetes
What this study did
NCT03921554 · Adeline Vanderver, MD
2019-06-03 – 2024-03-25 · Aicardi Goutieres Syndrome
What this study did
NCT05446831 · Peking University People's Hospital
2022-07-13 – 2023-12-01 · ITP, Immune Thrombocytopenia
What this study did
NCT04208464 · University of Manchester
2021-10-07 – 2023-09-25 · Idiopathic Inflammatory Myopathies
What this study did
NCT05263505 · Washington University School of Medicine
2022-02-21 – 2023-09-11 · Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
What this study did
NCT04027101 · University Hospital, Brest
2020-12-01 – 2023-08-30 · Polymyalgia Rheumatic (PMR)
What this study did
NCT05188521 · Aaron R. Mangold
2022-01-11 – 2023-05-17 · Cutaneous Lichen Planus
What this study did
NCT04822584 · University Hospital, Bordeaux
2021-07-16 – 2023-04-26 · Vitiligo
What this study did
NCT05361109 · University of Washington
2022-06-01 – 2023-03-31 · Dermatomyositis
What this study did
Phase 1/2 (5)
Other / comorbidity
NCT07535645 · Peking University People's Hospital
2026-03-09 – 2029-09-15 · Persistent Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation
What this study did
NCT06548802 · Tianjin Medical University General Hospital
2024-02-29 – 2026-12-31 · Pulmonary Injury After Intracerebral Hemorrhage
What this study did
NCT05189106 · Massachusetts General Hospital
2022-12-05 – 2025-06-20 · Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
What this study did
NCT02759731 · National Cancer Institute (NCI)
2016-11-01 – 2024-05-30 · Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease
What this study did
NCT04916756 · Peking Union Medical College Hospital
2020-01-16 – 2021-03-25 · Sjogren's Syndrome
What this study did
Phase 1 (24)
Alopecia Areata
NCT06545110 · South Valley University
2023-09-01 – 2024-10-30 · Alopecia Areata
What this study did
Atopic Dermatitis
NCT07262983 · National Institute of Allergy and Infectious Diseases (NIAID)
2026-11-24 – 2030-10-01 · Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome, HIES, Lupus, Atopic Dermatitis
What this study did
Rheumatoid Arthritis
NCT01398475 · Eli Lilly and Company
2011-07 – 2011-09 · Chronic Inflammatory Disorder, Arthritis, Rheumatoid
What this study did
Other / comorbidity
NCT05792462 · Tianjin Medical University General Hospital
2023-04-15 – 2027-03-01 · NMO Spectrum Disorder
What this study did
NCT07843693 · AbbVie
2026-08-26 – 2026-12 · Healthy Volunteers
What this study did
NCT03945760 · Wright State Physicians
2020-09-14 – 2023-10-16 · Allergic Contact Dermatitis
What this study did
NCT04131738 · Washington University School of Medicine
2020-04-07 – 2022-08-17 · Graft-versus-host-disease, Graft Vs Host Disease
What this study did
NCT03212638 · Eli Lilly and Company
2017-06-27 – 2017-11-01 · Healthy
What this study did
NCT02758613 · Eli Lilly and Company
2016-05 – 2016-07 · Healthy
What this study did
NCT02340104 · Eli Lilly and Company
2015-01 – 2015-02 · Healthy Volunteers
What this study did
NCT02263911 · Eli Lilly and Company
2014-11 – 2014-12 · Healthy Participants
What this study did
NCT01968057 · Eli Lilly and Company
2013-10 – 2013-12 · Healthy Volunteers
What this study did
NCT01960140 · Eli Lilly and Company
2013-10 – 2013-12 · Healthy Volunteers
What this study did
NCT01924299 · Eli Lilly and Company
2013-08 – 2013-11 · Healthy Volunteers
What this study did
NCT01937026 · Eli Lilly and Company
2013-09 – 2013-11 · Healthy Volunteers
What this study did
NCT01925144 · Eli Lilly and Company
2013-10 – 2013-11 · Healthy Volunteers
What this study did
NCT01896726 · Eli Lilly and Company
2013-07 – 2013-10 · Healthy Volunteers
What this study did
NCT01910311 · Eli Lilly and Company
2013-08 – 2013-10 · Healthy Volunteers
What this study did
NCT01859078 · Eli Lilly and Company
2013-05 – 2013-08 · Healthy Volunteers
What this study did
NCT01870388 · Eli Lilly and Company
2013-06 – 2013-07 · Liver Diseases, Hepatic Insufficiency
What this study did
NCT01536951 · Eli Lilly and Company
2012-02 – 2013-05 · Healthy Participants
What this study did
NCT01247350 · Eli Lilly and Company
2010-11 – 2011-04 · Healthy Volunteer
What this study did
NCT01299285 · Eli Lilly and Company
2011-02 – 2011-03 · Healthy Volunteers
What this study did
Phase 4 (12)
COVID-19
NCT04390464 · Cambridge University Hospitals NHS Foundation Trust
2020-05-08 – 2022-05-01 · COVID19
What this study did
Rheumatoid Arthritis
NCT06687551 · University Hospital, Toulouse
2025-06-06 – 2029-04-01 · Rheumatoid Arthritis (RA
What this study did
NCT07357649 · Tanta University
2026-01 – 2026-12 · Rheumatoid Arthritis
What this study did
NCT05955066 · Chinese University of Hong Kong
2023-12-01 – 2026-06 · Rheumatoid Arthritis
What this study did
NCT03915964 · Eli Lilly and Company
2019-04-25 – 2025-05-28 · Rheumatoid Arthritis
What this study did
NCT04086745 · Eli Lilly and Company
2020-02-14 – 2025-05-19 · Rheumatoid Arthritis
What this study did
NCT05080218 · Jeffrey Curtis
2021-11-15 – 2024-05-28 · Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
What this study did
NCT05827497 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2023-04-01 – 2024-03-31 · Rheumatoid Arthritis
What this study did
NCT05660655 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2022-10-01 – 2023-09-30 · Rheumatoid Arthritis
What this study did
NCT05238896 · Assistance Publique - Hôpitaux de Paris
2022-06-27 – 2023-03-31 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT05300932 · Tongji Hospital
2022-03-08 – 2026-11-12 · Systemic Sclerosis
What this study did
NCT06240351 · University of Alabama at Birmingham
2024-04-22 – 2026-09-16 · Frontal Fibrosing Alopecia
What this study did
Early phase / not applicable (7)
Alopecia Areata
NCT07645430 · Benha University
2023-01-01 – 2026-06-09 · Alopecia Areata
What this study did
Atopic Dermatitis
NCT05969730 · Mazandaran University of Medical Sciences
2023-08-15 – 2025-11-14 · Atopic Dermatitis
What this study did
COVID-19
NCT05279391 · Democritus University of Thrace
2020-10-25 – 2023-12-31 · COVID-19 Severe Respiratory Failure
What this study did
NCT05082714 · University Hospital of Patras
2021-10-20 – 2022-06-04 · COVID-19
What this study did
Rheumatoid Arthritis
NCT05003310 · Galvani Bioelectronics
2021-10-19 – 2032-04 · Rheumatoid Arthritis
What this study did
NCT06977035 · Sohag University
2025-05-05 – 2026-06 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT05781516 · Wen Zhang
2023-01-20 – 2025-06 · IgG4-related Disease With Eosinophilia
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
Alopecia Areata
NCT07554222 · Innovent Biologics (Suzhou) Co. Ltd.
2026-04-18 – 2028-12-31 · Healthy, Active Non-segmental Vitiligo, Severe Alopecia Areata
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT05897372 · Iain Bressendorff
2023-08-01 – 2024-09-23 · Diabetic Kidney Disease
What this study did

Competitive landscape

This mechanism is crowded: 9 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Atopic Dermatitis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Baricitinib (Olumiant): this drugPhase 3Small moleculeJAK, JAK1/2Reliable signal
NCT03334422: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5%
NCT03334396: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib) (16 Weeks): 2 mg Baricitinib 11.4% | 4 mg Baricitinib 16.8% vs Placebo 4.8%
Abrocitinib (Cibinqo)ApprovedSmall moleculeJAK1Reliable signal
NCT04345367: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30)
NCT03349060: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12 (Baseline, Week 12): PF-04965842 100 mg 23.7% | PF-04965842 200 mg 43.8% vs Placebo 7.9%
Crisaborole (Eucrisa)ApprovedSmall moleculePDE4Reliable signal
NCT02118766: Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 (Day 29): AN2728 Topical Ointment, 2 Percent 32.8% vs AN2728 Topical Ointment, Vehicle 25.4%
NCT02118792: Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29 (Day 29): AN2728 Ointment, 2 Percent (%) 31.4% vs AN2728 Ointment, Vehicle 18%
Difamilast (Moizerto / Adquey)ApprovedSmall moleculePDE4Partial signal
NCT03908970: Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): 1% OPA-15406 38.46% (95% CI 31.36 to 45.95) vs Placebo 12.64% (95% CI 8.18 to 18.36)
NCT03911401: IGA success (score 0 or 1 with at least a 2-grade improvement) at week 4: difamilast 0.3% 44.6% and 1% 47.1% vs vehicle 18.1%; p<0.001 for each dose vs vehicle. n=83, 85, 83 (Saeki 2022, Br J Dermatol).
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaWeak signal
NCT04417894: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7%
NCT03345914: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 (Week 16): Dupilumab 300 mg Q4W + TCS 32.8% | Dupilumab 100 mg or 200 mg Q2W + TCS 29.5% vs Placebo + TCS 11.4%
Lebrikizumab (Ebglyss)ApprovedMonoclonal antibodyIL-13Reliable signal
NCT04178967: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9)
NCT04146363: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 43.1% (95% CI 37.1 to 49) vs Placebo 12.7% (95% CI 7 to 18.5)
Nemolizumab (Nemluvio)ApprovedMonoclonal antibodyIL-31 receptor AReliable signal
NCT03989349: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 37.7% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 26%
NCT03985943: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 35.6% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 24.6%
Roflumilast (Zoryve)ApprovedSmall moleculePDE4Reliable signal
NCT06631170: Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001)
NCT04773600: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 (Week 4): Roflumilast Cream 0.15% 28.9% vs Vehicle Cream 12%
Ruxolitinib (Jakafi)
Approved(overall)
Small moleculeJAK1/2
Partial signal(overall)
No reviewed efficacy summary in this indication
Ruxolitinib (Opzelura)ApprovedSmall moleculeJAK1/2Reliable signal
NCT03745638: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5)
NCT03745651: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 39% (95% CI 32.6 to 45.6) | VC Period: Ruxolitinib 1.5% Cream BID 51.3% (95% CI 44.6 to 58) vs VC Period: Vehicle Cream BID 7.6% (95% CI 3.5 to 14)
TapinarofApprovedSmall moleculeAryl hydrocarbon receptor, Aryl Hydrocarbon Receptor AgonistReliable signal
NCT05014568: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 45.4% vs Vehicle Cream 13.9%
NCT05032859: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 46.4% vs Vehicle Cream 18%
Tralokinumab (Adbry)ApprovedMonoclonal antibodyIL-13Reliable signal
NCT05958407: Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9)
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03607422: EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo).
NCT03569293: EASI-75 at week 16 (Measure Up 1): 70% (196/281) upadacitinib 15mg, 80% (227/285) upadacitinib 30mg, vs 16% (46/281) placebo; adjusted difference vs placebo 53.3% [46.4-60.2] and 63.4% [57.1-69.8] respectively, both p<0.0001
ADSTEMPhase 3Cell therapyautologous adipose-derived mesenchymal stem cell (AD-MSC) therapynot yet gradedNo reviewed efficacy summary in this indication
AsivatrepPhase 3Small moleculeTRPV1Reliable signal
NCT02965118: IGA success (score 0 or 1) at week 8: 36.0% asivatrep vs 12.8% vehicle (P<.001)
GS101Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Ivarmacitinib
Phase 3(overall)
Small moleculeJAK
not yet graded(overall)
No reviewed efficacy summary in this indication
Jaktinib (Zepuping)Phase 3Small moleculeJAK1/2/3Partial signalNo reviewed efficacy summary in this indication
LW402Phase 3Small moleculeJAK1Partial signalNo reviewed efficacy summary in this indication
ManfidokimabPhase 3Monoclonal antibodyIL-4R-alphaPartial signalNo reviewed efficacy summary in this indication
PumecitinibPhase 3Small moleculeJAK1/2not yet gradedNo reviewed efficacy summary in this indication
QL2108Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
QLM3003Phase 3Small moleculeJAKPartial signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphaPartial signal
NCT05017480: vIGA 0/1 with a reduction of 2 points or more at week 16: rademikibart 300 mg Q2W 29.0% vs placebo 5.9%, P<0.001 (SEASIDE CHINA, Br J Dermatol 2026).
RezpegaldesleukinPhase 3Protein / enzyme therapeuticIL-2 mutein (Treg-selective)not yet gradedNo reviewed efficacy summary in this indication
SHR-1819Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Soficitinib (ICP-332)Phase 3Small moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
SSGJ-611Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
StapokibartPhase 3Monoclonal antibodyIL-4R-alphaReliable signal
NCT06277765: EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001)
NCT05265923: EASI-75 response at week 16: 66.9% stapokibart vs 25.8% placebo (significantly higher)
TelikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VC005Phase 3Small moleculeJAK1, JAK1not yet gradedNo reviewed efficacy summary in this indication
ZemprocitinibPhase 3Small moleculeJAK1Reliable signal
NCT06277245: EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001)
AfimkibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
BarzolvolimabPhase 2Monoclonal antibodyKITnot yet gradedNo reviewed efficacy summary in this indication
BempikibartPhase 2Monoclonal antibodyIL-7 receptor alphanot yet gradedNo reviewed efficacy summary in this indication
BFB759Phase 2Monoclonal antibodyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
BosakitugPhase 2Monoclonal antibodyTSLPWeak signal
NCT05932654: Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26 (Week 26): 300 mg 94.1% (95% CI 71.3 to 99.9)
CamoteskimabPhase 2Monoclonal antibodyIL-18Partial signalNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13Weak signalFeatured results are safety only in this race
CMS-D001Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—Weak signalFeatured results are safety only in this race
EVO101Phase 2Small moleculeIRAK4Partial signal
NCT05579899: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): EVO101 Cream -43.5% (Standard Deviation 60.85) vs Vehicle Cream -62% (Standard Deviation 38.78) missed
EVO301Phase 2Protein / enzyme therapeuticIL-18Partial signal
NCT06723405: Placebo-adjusted improvement in EASI at Week 12: 33% (95% CI -50, -17; p<0.01)
FB825Phase 2Monoclonal antibodyCεmX domain of membrane-bound IgE (mIgE)Weak signalNo reviewed efficacy summary in this indication
FelcorekibartPhase 2Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
GalvokimigPhase 2Multispecific antibodyIL-13, IL-17A, IL-17FPartial signalFeatured results are safety only in this race
GHZ339Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
GIA632Phase 2Monoclonal antibodyIL-15not yet gradedNo reviewed efficacy summary in this indication
HSK44459Phase 2Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
HY209gelPhase 2Small moleculeGPCR19 / GPBAR1 (TGR5, bile acid receptor)Partial signalFeatured results are safety only in this race
IN-115314Phase 2Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
JNJ-95597528Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
JYP0061Phase 2Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6Weak signalFeatured results are safety only in this race
LepzacitinibPhase 2Small moleculeJAK1/JAK3not yet gradedNo reviewed efficacy summary in this indication
LNK01004Phase 2Small moleculePan-JAKPartial signalFeatured results are safety only in this race
LT-002-158Phase 2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
LutikizumabPhase 2Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
ModzatinibPhase 2Small moleculeITK and JAK3not yet gradedNo reviewed efficacy summary in this indication
MosedipimodPhase 2Small moleculeNF-kB / CCL26 pathwaynot yet gradedNo reviewed efficacy summary in this indication
Nitrosomonas Eutropha (B244)Phase 2Microbiome therapeuticlive biotherapeutic (topical ammonia-oxidizing bacterium, AOBiome/B244)Reliable signal
NCT04490109: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS) (Baseline to Day 28): B244 O.D. 5.0 -2.8 score on a scale (Standard Error 0.184) | B244 O.D. 20.0 -2.8 score on a scale (Standard Error 0.184) vs Vehicle -2.1 score on a scale (Standard Error 0.18)
OlevaprubartPhase 2Monoclonal antibodyOX40Weak signalFeatured results are safety only in this race
OmpekimigPhase 2Multispecific antibodyIL-4, IL-13, IL-33Partial signal
NCT05995964: Stage 1, high-dose ompekimig vs placebo: met the primary endpoint (EASI-75 at week 16); no ompekimig figures were given (2026-03-09).
OpSCFPhase 2Monoclonal antibodyStem cell factor (SCF / KIT ligand)Partial signal
NCT06101823: Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 16 (Baseline, Week 16): OpSCF 600 mg -71.476 percent change (Standard Error 8.6876) | OpSCF Matching-Placebo -50.992 percent change (Standard Error 8.8073)
ZL-82Phase 2Small moleculeJAKnot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 67 furthest-along competitors are listed; 47 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Olumiant (baricitinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 1Healthy VolunteersRecruiting
Est. primary completion 2026-12 · NCT07843693 · CT.gov ↗
What to watch
Phase 1/2Pulmonary Injury After Intracerebral HemorrhageActive not recruiting
Est. primary completion 2026-12-31 · NCT06548802 · CT.gov ↗
What to watch
Phase 2Spontaneous Subarachnoid HemorrhageNot yet recruiting
Est. primary completion 2026-12-31 · NCT06439615 · CT.gov ↗
What to watch
2027 (9)
March 2027 (2)
Phase 3Rheumatoid ArthritisActive not recruiting
Est. primary completion 2027-03 · NCT04870203 · CT.gov ↗
What to watch
Phase 1NMO Spectrum DisorderActive not recruiting
Est. primary completion 2027-03-01 · NCT05792462 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Behcet Syndrome, Intestinal TypeRecruiting
Est. primary completion 2027-06-30 · NCT06849908 · CT.gov ↗
What to watch
July 2027 (1)
Early phase / not applicableRheumatoid ArthritisRecruiting
Est. primary completion 2027-07 · NCT05003310 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2/3Acute Ichemic Stroke, Anterior Cerebral Artery Stroke, BaricitinibNot yet recruiting
Est. primary completion 2027-08-17 · NCT07449910 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Depressive Symptoms, Cognitive SymptomRecruiting
Est. primary completion 2027-10 · NCT07608796 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2HIV, Depression, AnhedoniaRecruiting
Est. primary completion 2027-11 · NCT05849038 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1/2Persistent Thrombocytopenia, Allogeneic Hematopoietic Stem Cell TransplantationRecruiting
Est. primary completion 2027-12-31 · NCT07535645 · CT.gov ↗
What to watch
Phase 2ITP - Immune ThrombocytopeniaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07669675 · CT.gov ↗
What to watch
2028 (12)
January 2028 (2)
Phase 2Human Immunodeficiency VirusRecruiting
Est. primary completion 2028-01 · NCT05452564 · CT.gov ↗
What to watch
Phase 2HIV Infection, HIVNot yet recruiting
Est. primary completion 2028-01 · NCT07209267 · CT.gov ↗
What to watch
February 2028 (1)
Phase 3DermatomyositisRecruiting
Est. primary completion 2028-02-28 · NCT04972760 · CT.gov ↗
What to watch
March 2028 (2)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
Phase 3Alopecia AreataRecruiting
Est. primary completion 2028-03 · NCT05723198 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3COVID-19Recruiting
Est. primary completion 2028-06 · NCT02735707 · CT.gov ↗
What to watch
July 2028 (2)
Phase 3Diabetes Mellitus, Type 1Recruiting
Est. primary completion 2028-07 · NCT07222332 · CT.gov ↗
What to watch
Phase 2Cardiac SarcoidosisRecruiting
Est. primary completion 2028-07-01 · NCT06868381 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2SepsisRecruiting
Est. primary completion 2028-08-09 · NCT06381661 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2Inflammatory Hepatocellular AdenomaRecruiting
Est. primary completion 2028-09-02 · NCT06490757 · CT.gov ↗
What to watch
Phase 3COVID-19Recruiting
Est. primary completion 2028-09-30 · NCT04381936 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3Polymyalgia Rheumatica (PMR)Recruiting
Est. primary completion 2028-11 · NCT07279688 · CT.gov ↗
What to watch
2029 (5)
April 2029 (1)
Phase 4Rheumatoid ArthritisRecruiting
Est. primary completion 2029-04-01 · NCT06687551 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2HIV-1-infectionNot yet recruiting
Est. primary completion 2029-05 · NCT07081763 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2ARDS (Acute Respiratory Distress Syndrome), Acute Hypoxic Respiratory FailureNot yet recruiting
Est. primary completion 2029-09 · NCT07779642 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Folliculitis Decalvans (FD)Not yet recruiting
Est. primary completion 2029-11-01 · NCT07268534 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Active Non-anterior Non-infectious UveitisNot yet recruiting
Est. primary completion 2029-12 · NCT05651880 · CT.gov ↗
What to watch
2030 (4)
February 2030 (1)
Phase 2Major Depressive DisorderRecruiting
Est. primary completion 2030-02 · NCT07003997 · CT.gov ↗
What to watch
May 2030 (1)
Phase 1Atopic DermatitisRecruiting
Est. primary completion 2030-05-01 · NCT07262983 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections …Not yet recruiting
Est. primary completion 2030-07-31 · NCT07543458 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Kohlmeier-Degos Disease, Malignant Atrophic Papulosis, Degos Disease, Papulosis, Malignant AtrophicRecruiting
Est. primary completion 2030-12-14 · NCT06923072 · CT.gov ↗
What to watch
2031 (2)
July 2031 (2)
Phase 3Diabetes Mellitus, Type 1Recruiting
Est. primary completion 2031-07 · NCT07222137 · CT.gov ↗
What to watch
Phase 3Juvenile Idiopathic ArthritisRecruiting
Est. primary completion 2031-07 · NCT03773965 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 September 2026ApprovalFDA approves Olumiant for adolescents with severe alopecia areata
US, FDA · Eli Lilly and Company · Source ↗
27 February 2026Filing submittedOlumiant US submission for adolescent severe alopecia areata
US, FDA · Source ↗